Comparing Cancer Incidence in an Observational Cohort of Medicaid Beneficiaries With and Without HIV, 2001-2015

Comparing Cancer Incidence in an Observational Cohort of Medicaid Beneficiaries With and Without HIV, 2001-2015

Published: Jan 01, 2024
Publisher: Journal of Acquired Immune Deficiency Syndromes, vol. 95, issue 1
Download
Authors

Jacqueline E. Rudolph

Xiaoqiang Xu

Eryka Wentz

Filip Pirsl

Kala Visvanathan

Bryan Lau

Corinne Joshu

Background

Life expectancy among people with HIV (PWH) is increasing, making chronic conditions—including cancer—increasingly relevant. Among PWH, cancer burden has shifted from AIDS-defining cancers (ADCs) toward non-AIDS-defining cancers (NADCs).

Setting

We described incidence of cancer in a claims-based cohort of Medicaid beneficiaries. We included 43,426,043 Medicaid beneficiaries (180,058 with HIV) from 14 US states, aged 18-64, with >6 months of enrollment (with no dual enrollment in another insurance) and no evidence of a prior cancer.

Methods

We estimated cumulative incidence of site-specific cancers, NADCs, and ADCs by baseline HIV status, using age as the time scale and accounting for death as a competing risk. We compared cumulative incidence across HIV status to estimate risk differences. We examined cancer incidence overall and by sex, race/ethnicity, and calendar period.

Results

PWH had a higher incidence of ADCs, infection-related NADCs, and death. For NADCs like breast, prostate, and colon cancer, incidence was similar or higher among PWH below age 50 but higher among those without HIV by age 65. Incidence of lung and head and neck cancer was always higher for female beneficiaries with HIV, while the curves crossed for male beneficiaries. We saw only small differences in incidence trends by race/ethnicity.

Conclusion

Our findings suggest an increased risk of certain NADCs at younger ages among PWH, even when compared against other Medicaid beneficiaries, and highlight the importance of monitoring PWH for ADCs and NADCs. Future work should explore possible mechanisms explaining the differences in incidence for specific cancer types.

How do you apply evidence?

Take our quick four-question survey to help us curate evidence and insights that serve you.

Take our survey